BigBio.ai -- Verified Reads https://bigbio.ai/research Primary-source diligence on public biotech assets. Every claim two clicks from its source. Not investment advice; no buy/hold/sell. en-us Fri, 08 May 2026 12:00:00 GMT Moderna, Inc. (MRNA): Four prophylactic mRNA approvals shipped. mRNA-1010 PDUFA August 5; INTerpath-001 melanoma readout next. The strain-B liability that felled Sanofi and Pfizer/BioNTech still applies. https://bigbio.ai/research/mrna https://bigbio.ai/research/mrna Fri, 08 May 2026 12:00:00 GMT modRNA platform · seasonal respiratory + oncology. Four prophylactic mRNA approvals shipped. mRNA-1010 PDUFA August 5; INTerpath-001 melanoma readout next. The strain-B liability that felled Sanofi and Pfizer/BioNTech still applies. Corbus Pharmaceuticals Holdings (CRBP): CRB-701 ORR 47.6% in 2L head and neck. Zero peer-reviewed data. Pliant’s αvβ8 lead boxes out CRB-913. https://bigbio.ai/research/crbp https://bigbio.ai/research/crbp Tue, 05 May 2026 12:00:00 GMT nectin-4 ADC · 2L head and neck + cervical cancer. CRB-701 ORR 47.6% in 2L head and neck. Zero peer-reviewed data. Pliant’s αvβ8 lead boxes out CRB-913. Relay Therapeutics, Inc. (RLAY): Mechanism validated by prior art. The 490-patient ReFocus finished in September. The data still has not appeared. https://bigbio.ai/research/rlay https://bigbio.ai/research/rlay Mon, 04 May 2026 12:00:00 GMT FGFR2 + mutant-selective PI3Kα · solid tumors. Mechanism validated by prior art. The 490-patient ReFocus finished in September. The data still has not appeared. Immunome, Inc. (IMNM): Phase 3 hazard ratio 0.16. NDA filed April 29. ASCO oral on May 30 fills in subgroup detail. https://bigbio.ai/research/imnm https://bigbio.ai/research/imnm Fri, 01 May 2026 12:00:00 GMT gamma-secretase inhibitor · desmoid tumor. Phase 3 hazard ratio 0.16. NDA filed April 29. ASCO oral on May 30 fills in subgroup detail. IDEAYA Biosciences, Inc. (IDYA): OptimUM-02 hit. HR 0.42, mPFS 6.9 vs 3.1 mo. NDA H2 2026. ASCO LBA9503 fills in the rest June 1. https://bigbio.ai/research/idya https://bigbio.ai/research/idya Wed, 29 Apr 2026 12:00:00 GMT PKC inhibitor + c-MET · HLA*A2(-) metastatic uveal melanoma. OptimUM-02 hit. HR 0.42, mPFS 6.9 vs 3.1 mo. NDA H2 2026. ASCO LBA9503 fills in the rest June 1. Wave Life Sciences (WVE): GalNAc cleared 11 µM where one LNP didn’t. Beam’s LNP cleared it harder. https://bigbio.ai/research/wve https://bigbio.ai/research/wve Tue, 28 Apr 2026 12:00:00 GMT GalNAc-conjugated AIMer · alpha-1 antitrypsin deficiency. GalNAc cleared 11 µM where one LNP didn’t. Beam’s LNP cleared it harder. Compass Therapeutics (CMPX): Primary hit. Secondary hit. OS missed because 54% of placebo crossed over. https://bigbio.ai/research/cmpx https://bigbio.ai/research/cmpx Mon, 27 Apr 2026 12:00:00 GMT DLL4×VEGF-A bispecific · biliary tract cancer. Primary hit. Secondary hit. OS missed because 54% of placebo crossed over. Absci Corporation (ABSI): The AI designs antibodies. The clinic opened eleven months ago. https://bigbio.ai/research/absi https://bigbio.ai/research/absi Mon, 27 Apr 2026 12:00:00 GMT AI antibody design · oncology. The AI designs antibodies. The clinic opened eleven months ago.